Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
July 27, 2016 4:01 PM EDTWASHINGTON, July 27, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2016.
"Vanda's commercial business continues to demonstrate strong progress and growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "We look forward to our planned launch of HETLIOZ in Germany in the third quarter and the opportunity to bring an important therapy to Non-24 patients in Europe."
Key Highlights:
Total net product sales from HETLIOZ® and Fanapt® were $36.0 million during the second... More